Chronic inflammatory conditions along with dyslipidemia represent a significant portion of public health concerns which include cardiovascular and respiratory diseases. Impaired resolution of inflammation and lipoprotein metabolism dysfunction are well known factors of atherosclerosis development that along with altered host response signifies respiratory conditions as chronic obstructive pulmonary disease (COPD) and asthma. The fact that these nosologies are commonly associated with each other and have significant economic impact should raise further concern among health care professionals and patients advocates. Indeed, epidemiological studies have shown a high prevalence of these comorbidities in the general population but underlying pathophysiological mechanisms and clinical management are still ambiguous and need further exploration.
Chronic inflammatory conditions have been recently considered as risk-enhancing factors in managing blood cholesterol for the primary CVD prevention. However, only some aspects of respiratory diseases progression, such as smoking, has been taking into consideration. Metanalyses and national registries revealed a common presence of ischaemic heart disease, heart failure and arrhythmias in subjects with COPD and asthma. Moreover, accompanying pulmonary hypertension represents a significant health care concern. In this research topic collection of articles, we aimed to provide more insights into the biology, pathophysiology and clinical management of CVD and respiratory comorbidity by utilizing results from recent basic and translational research.
Specific themes we would like contributors to address include, but are not limited to:
1) Epidemiological studies on CVD risk in patients with respiratory conditions, specifically COPD and asthma (clinical studies, metanalyses.
2) Potential mechanisms of heart failure and arrhythmias development in COPD and asthma patients with emphasis on chronic inflammation, vascular and lipid dysfunction (original research articles).
3) Effects of lipoproteins on respiratory conditions pathophysiology (clinical, research articles, hypothesis).
4) Novel biochemical and clinical markers of CVD risk in patients with respiratory conditions, proteomics studies (clinical and review articles).
5) Genetic and artificial intelligent tools in predicting CVD outcomes/risk estimation in patients with respiratory conditions (original articles).
6) Experimental and novel treatment of CVD associated conditions in patients with respiratory diseases (original research and review articles).
7) Diet and nutrients application in altering inflammation, lipoprotein metabolism and respiratory function in patients with CVD and associated pulmonary conditions (original, clinical and review articles).
Chronic inflammatory conditions along with dyslipidemia represent a significant portion of public health concerns which include cardiovascular and respiratory diseases. Impaired resolution of inflammation and lipoprotein metabolism dysfunction are well known factors of atherosclerosis development that along with altered host response signifies respiratory conditions as chronic obstructive pulmonary disease (COPD) and asthma. The fact that these nosologies are commonly associated with each other and have significant economic impact should raise further concern among health care professionals and patients advocates. Indeed, epidemiological studies have shown a high prevalence of these comorbidities in the general population but underlying pathophysiological mechanisms and clinical management are still ambiguous and need further exploration.
Chronic inflammatory conditions have been recently considered as risk-enhancing factors in managing blood cholesterol for the primary CVD prevention. However, only some aspects of respiratory diseases progression, such as smoking, has been taking into consideration. Metanalyses and national registries revealed a common presence of ischaemic heart disease, heart failure and arrhythmias in subjects with COPD and asthma. Moreover, accompanying pulmonary hypertension represents a significant health care concern. In this research topic collection of articles, we aimed to provide more insights into the biology, pathophysiology and clinical management of CVD and respiratory comorbidity by utilizing results from recent basic and translational research.
Specific themes we would like contributors to address include, but are not limited to:
1) Epidemiological studies on CVD risk in patients with respiratory conditions, specifically COPD and asthma (clinical studies, metanalyses.
2) Potential mechanisms of heart failure and arrhythmias development in COPD and asthma patients with emphasis on chronic inflammation, vascular and lipid dysfunction (original research articles).
3) Effects of lipoproteins on respiratory conditions pathophysiology (clinical, research articles, hypothesis).
4) Novel biochemical and clinical markers of CVD risk in patients with respiratory conditions, proteomics studies (clinical and review articles).
5) Genetic and artificial intelligent tools in predicting CVD outcomes/risk estimation in patients with respiratory conditions (original articles).
6) Experimental and novel treatment of CVD associated conditions in patients with respiratory diseases (original research and review articles).
7) Diet and nutrients application in altering inflammation, lipoprotein metabolism and respiratory function in patients with CVD and associated pulmonary conditions (original, clinical and review articles).
